Logo image of B8FK.DE

BIOFRONTERA AG (B8FK.DE) Stock Fundamental Analysis

FRA:B8FK - Deutsche Boerse Ag - DE000A4BGGM7 - Common Stock - Currency: EUR

2.48  -0.05 (-1.98%)

Fundamental Rating

1

B8FK gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 52 industry peers in the Pharmaceuticals industry. B8FK may be in some trouble as it scores bad on both profitability and health. B8FK is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

B8FK had negative earnings in the past year.
In the past year B8FK has reported a negative cash flow from operations.
In the past 5 years B8FK reported 4 times negative net income.
B8FK had negative operating cash flow in 4 of the past 5 years.
B8FK.DE Yearly Net Income VS EBIT VS OCF VS FCFB8FK.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 0 20M -20M -40M

1.2 Ratios

B8FK's Return On Assets of -14.67% is on the low side compared to the rest of the industry. B8FK is outperformed by 76.00% of its industry peers.
With a Return On Equity value of -23.07%, B8FK is not doing good in the industry: 76.00% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -14.67%
ROE -23.07%
ROIC N/A
ROA(3y)-50.28%
ROA(5y)N/A
ROE(3y)-80.7%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
B8FK.DE Yearly ROA, ROE, ROICB8FK.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 0 50 -50 -100 -150 -200

1.3 Margins

The Gross Margin of B8FK (75.41%) is better than 74.00% of its industry peers.
In the last couple of years the Gross Margin of B8FK has declined.
B8FK does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 75.41%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.43%
GM growth 5YN/A
B8FK.DE Yearly Profit, Operating, Gross MarginsB8FK.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024 0 100 -100

More info and screens

3

2. Health

2.1 Basic Checks

B8FK does not have a ROIC to compare to the WACC, probably because it is not profitable.
B8FK has more shares outstanding than it did 1 year ago.
Compared to 1 year ago, B8FK has an improved debt to assets ratio.
B8FK.DE Yearly Shares OutstandingB8FK.DE Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 2M 4M 6M
B8FK.DE Yearly Total Debt VS Total AssetsB8FK.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

B8FK has an Altman-Z score of -4.70. This is a bad value and indicates that B8FK is not financially healthy and even has some risk of bankruptcy.
B8FK's Altman-Z score of -4.70 is on the low side compared to the rest of the industry. B8FK is outperformed by 80.00% of its industry peers.
B8FK has a Debt/Equity ratio of 0.02. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.02, B8FK belongs to the top of the industry, outperforming 92.00% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Altman-Z -4.7
ROIC/WACCN/A
WACC6.94%
B8FK.DE Yearly LT Debt VS Equity VS FCFB8FK.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 20M 40M

2.3 Liquidity

A Current Ratio of 1.55 indicates that B8FK should not have too much problems paying its short term obligations.
The Current ratio of B8FK (1.55) is better than 66.00% of its industry peers.
B8FK has a Quick Ratio of 1.02. This is a normal value and indicates that B8FK is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of B8FK (1.02) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 1.55
Quick Ratio 1.02
B8FK.DE Yearly Current Assets VS Current LiabilitesB8FK.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 5M 10M 15M

More info and screens

0

3. Growth

3.1 Past

The earnings per share for B8FK have decreased strongly by -915.32% in the last year.
Looking at the last year, B8FK shows a very negative growth in Revenue. The Revenue has decreased by -32.82% in the last year.
B8FK shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -9.04% yearly.
EPS 1Y (TTM)-915.32%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%122.55%
Revenue 1Y (TTM)-32.82%
Revenue growth 3Y-9.04%
Revenue growth 5YN/A
Sales Q2Q%55.35%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y124.55%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year22.18%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
B8FK.DE Yearly Revenue VS EstimatesB8FK.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M 50M
B8FK.DE Yearly EPS VS EstimatesB8FK.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -2 -4 -6

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for B8FK. In the last year negative earnings were reported.
Based on the Price/Forward Earnings ratio of 22.64, the valuation of B8FK can be described as rather expensive.
The rest of the industry has a similar Price/Forward Earnings ratio as B8FK.
When comparing the Price/Forward Earnings ratio of B8FK to the average of the S&P500 Index (36.44), we can say B8FK is valued slightly cheaper.
Industry RankSector Rank
PE N/A
Fwd PE 22.64
B8FK.DE Price Earnings VS Forward Price EarningsB8FK.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
B8FK.DE Per share dataB8FK.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

B8FK does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BIOFRONTERA AG

FRA:B8FK (7/18/2025, 7:00:00 PM)

2.48

-0.05 (-1.98%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-31 2025-05-31
Earnings (Next)09-29 2025-09-29
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners12.23%
Ins Owner ChangeN/A
Market Cap15.08M
Analysts82.86
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 22.64
P/S 0.7
P/FCF N/A
P/OCF N/A
P/B 0.8
P/tB 0.84
EV/EBITDA N/A
EPS(TTM)-0.12
EYN/A
EPS(NY)0.11
Fwd EY4.42%
FCF(TTM)-0.45
FCFYN/A
OCF(TTM)-0.42
OCFYN/A
SpS3.56
BVpS3.1
TBVpS2.94
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -14.67%
ROE -23.07%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 75.41%
FCFM N/A
ROA(3y)-50.28%
ROA(5y)N/A
ROE(3y)-80.7%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.43%
GM growth 5YN/A
F-Score2
Asset Turnover0.73
Health
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 25.03%
Cap/Sales 0.97%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.55
Quick Ratio 1.02
Altman-Z -4.7
F-Score2
WACC6.94%
ROIC/WACCN/A
Cap/Depr(3y)90.61%
Cap/Depr(5y)N/A
Cap/Sales(3y)2.54%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-915.32%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%122.55%
EPS Next Y124.55%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-32.82%
Revenue growth 3Y-9.04%
Revenue growth 5YN/A
Sales Q2Q%55.35%
Revenue Next Year22.18%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-208.45%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year131.82%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y2.41%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-33.28%
OCF growth 3YN/A
OCF growth 5YN/A